Skip to main content

Drug Interactions between busulfan and Casgevy

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

busulfan exagamglogene autotemcel

Applies to: busulfan and Casgevy (exagamglogene autotemcel)

ADJUST DOSING INTERVAL: Concurrent use of the autologous genome edited hematopoietic stem cell-based gene therapy exagamglogene autotemcel with myeloablative conditioning agents, such as busulfan, may lead to destruction of the newly edited stem cells. However, clinical data on the use of exagamglogene autotemcel before elimination of the myeloablative conditioning regimen are not available.

MANAGEMENT: The manufacturer recommends administering exagamglogene autotemcel between a minimum of 48 hours and a maximum of 7 days after the last dose of the myeloablative conditioning regimen, to allow for the elimination of the myeloablative conditioning agent from the body.

References (2)
  1. (2023) "Product Information. Casgevy (exagamglogene autotemcel)." Vertex Pharmaceuticals
  2. Vertex Pharmaceuticals (Europe) Limited (2024) Casgevy 4-13 x 10Exp6 cells/mL dispersion for infusion https://www.medicines.org.uk/emc/product/15296

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer